β2-Arrestin germline knockout does not attenuate opioid respiratory depression

Iris Bachmutsky^{1,2}, Adela Durand¹, Kevin Yackle^{1†}

¹Department of Physiology, University of California-San Francisco

San Francisco, CA 94143, USA

²Neuroscience Graduate Program, University of California-San Francisco

San Francisco, CA 94143, USA

[†] Correspondence to: Kevin Yackle, kevin.yackle@ucsf.edu, 415-514-7309 (phone)

Abstract

Opioids are perhaps the most effective analgesics in medicine. However, from 1999 to 2018,
25 they also killed more than 400,000 people in the United States by suppressing breathing, a
common side-effect known as opioid induced respiratory depression. This doubled-edged sword
has inspired the dream of developing novel therapeutics that provide opioid-like analgesia
without respiratory depression. One such approach has been to develop so-called ‘biased
agonists’ that activate some, but not all pathways downstream of the μ -opioid receptor (MOR),
30 the target of morphine and other opioid analgesics. This hypothesis stems from a study
suggesting that MOR-mediated activation of β 2-Arrestin is the downstream signaling pathway
responsible for respiratory depression, whereas inhibition of adenylyl cyclase produces
analgesia. To further verify this model, which represents the motivation for the biased agonist
approach, we examined respiratory behavior in mice lacking the gene for β 2-Arrestin. Contrary
35 to previous findings, we find no correlation between β 2-Arrestin function and opioid-induced
respiratory depression, suggesting that any effect of biased agonists must be mediated through an
as-yet to be identified signaling mechanism.

Introduction

More than 180 people died each day in 2018 from suppression of breathing induced by opioid

overdose, a lethal effect commonly referred to as opioid induced respiratory depression

(OIRD)^{1,2}. Nevertheless, opioids remain among the best and most effective and widely

prescribed analgesics, as evidenced by the World Health Organization's step ladder for pain

management. These two contrasting characteristics have created the urgent desire to develop or

discover novel MOR agonists that provide analgesia without depressing breathing. Such a

possibility emerged in 2005 when it was reported that mice with germline deletion of β 2-arrestin

(*Arrb2*^{-/-}) experience enhanced analgesia with attenuated respiratory suppression when

administered systemic morphine³. This finding inspired a new field of 'biased agonist'

pharmacology, which remains a central strategy in drug discovery for analgesics⁴.

Germline deletion of the μ -opioid receptor gene (*Oprm1*) completely eliminates OIRD in

murine models⁵ and selective deletion of *Oprm1* within the brainstem medullary breathing

rhythm generator, the preBötzinger Complex (preBötC)⁶, greatly attenuates OIRD in normoxic

and hypercapnic air^{7,8}. When engaged, MOR Gi-protein signaling activates inwardly rectifying potassium channels⁹ and inhibits synaptic vesicle release¹⁰, thereby depressing neural signaling.

Additionally, MOR can signal intracellularly in a pathway that depends on MOR internalization

by *Arrb2*^{11,12}. Indeed, all three pathways have been implicated in OIRD^{3,13,14} but a role for *Arrb2*

has been suggested to be important and selective for respiratory depression, relative to analgesia.

Since the original OIRD study of *Arrb2*^{-/-} mice, multiple MOR agonists, dubbed "biased"

agonists, have been created that signal through Gi, but not *Arrb2*, pathways, and which produce

analgesia with reduced respiratory depression^{15,16}. These studies have provided pharmacological

support for the proposed role of β 2-Arrestin in OIRD.

More recently, however, results of these studies have been called into question^{17,18}, prompting us to independently investigate the underlying necessity of *Arrb2* in mediating OIRD. Here, in an experiment where we rigorously control for genetic background, we demonstrate that basal breathing and OIRD are similar in *Arrb2*^{+/+}, *Arrb2*^{+/-}, and *Arrb2*^{-/-} littermates.

65 Furthermore, the *in vitro* preBötC rhythm is similarly silenced by an MOR agonist in *Arrb2*^{-/-} and wildtype animals. Our data, together with another recent report, calls into question the necessary role of *Arrb2* in opioid induced respiratory depression and suggests that MOR biased agonists attenuate OIRD through a different mechanism.

70 Results

Breathing behaviors and OIRD severity differ between strains of mice¹⁹. Therefore, we sought to compare basal and morphine modulated breathing in mice with the same genetic background. We bred F1 *Arrb2*^{+/-} mice to generate littermates that were wildtype (^{+/+}), heterozygous (^{+/-}), and homozygous (^{-/-}) for germline deletion of *Arrb2* (Figure 1a). Breathing was assessed by
75 whole-body plethysmography following intraperitoneal (IP) injection of saline (for control recordings) or after IP morphine (20mg/kg, Figure 1a). This same breathing protocol was conducted in both normoxia (21% O₂) and hypercapnia (5% CO₂, 21% O₂). Although hypercapnia is a non-physiologic gas, it minimizes fluctuations seen in baseline normoxia breathing rate that may confound OIRD quantification. We used our previously described
80 analytical pipeline⁷ to assay the two key parameters that define OIRD: slow and shallow breathing. Slow breathing is measured as the instantaneous frequency of each breath and shallow breathing is defined by the peak inspiratory flow since it strongly correlates with the amount of air inspired (PIF, Figure 1b).

After IP saline in normoxia, the morphology of single breaths and respiratory rhythm in *Abbr2* $+/+$ and $-/-$ mice appeared similar (Figure 1b-c). As expected with OIRD, after IP morphine the frequency and PIF decreased, although individual breaths and breathing rhythm remained indistinguishable in *Abbr2* $+/+$ versus $-/-$ mice (Figure 1d-e). Consistently, histograms of the instantaneous frequency for each breath after IP morphine showed overlapping peaks and distributions (centered near 2Hz) in *Arrb2* $+/+$ (combined from $n=5$ mice), $+/-$ ($n=6$), and $-/-$ ($n=7$) animals (Figure 1f). The ratio of average instantaneous frequency after IP morphine to IP saline was similar among the genotypes, where morphine decreased respiratory rate by 60% (Figure 1g). In fact, there was a statistically significant enhanced respiratory depression in *Arrb2* $-/-$ and $+/-$ mice compared to *Arrb2* $+/+$. Similarly, the PIF in morphine breathing histograms and ratio of IP morphine to IP saline were similar for *Arrb2* $-/-$ and $+/+$ genotypes (Figure 1h-i, PIF depressed by ~40%). These data demonstrate that OIRD in normoxia is not diminished in *Arrb2* $-/-$ mice.

These same breathing assays and analysis were performed in hypercapnia. Hypercapnia greatly reduces the variability of breathing that exists in normoxia caused by changes in behavior, like sniffing, grooming, calmly sitting, and sleeping. If these changes differ between mice, it may confound the quantification of OIRD. Although hypercapnia increases the frequency and depth of breathing, OIRD is still observed in this condition. As anticipated, hypercapnia made breathing very regular after IP saline and IP morphine (Figure 2a-d). We observed that breath morphology, depression of frequency (depressed by ~30%) and PIF (depressed by ~30%) were the same among all three genotypes (Figure 2), consistent with our conclusion that OIRD is not attenuated in *Arrb2*-deficient mice.

In addition to *in vivo* breathing, we examined the effects of the opioid peptide [D-Ala, *N*-MePhe, Gly-ol]-enkephalin (DAMGO) directly on the preBötC respiratory rhythm generator and key site for OIRD. The rhythmic activity was monitored by measuring electrical activity in the hypoglossal nerve rootlet⁶. DAMGO (50nM) was bath applied to slices from *Arrb2* ^{-/-} mice, which silenced the rhythm (Figure 3, n=3). This matches the concentration of DAMGO (50-100nM) needed to silence a wildtype C57BL/6 preBötC⁷. Importantly, the rhythm was restored in the presence of the MOR antagonist, naloxone (100nM), indicating slice viability (Figure 3).

Discussion

Our *in vivo* results show that germline deletion of *Arrb2* did not attenuate opioid induced respiratory depression in normoxia nor hypercapnia. Given the effect size of previously reported results³, our cohorts were sufficiently powered (n>1-4 mice minimum) to observe a decrease in OIRD if it existed. Our statistical tests were even performed conservatively to detect a negative result, meaning no difference between *Arrb2*^{+/+} and ^{-/-}, by not correcting for multiple comparisons. Additionally, we found that the *in vitro* preBötC rhythm, a key site in OIRD⁷, is just as sensitive to DAMGO in brain slices from *Arrb2* ^{-/-} as wildtype mice. Combined, these results demonstrate that *Arrb2* germline knockout does not rescue OIRD.

This study was designed with four important features: First, we compared littermates in order to control for strain specific effects on breathing and opioid sensitivity¹⁹. Second, the comparison of breathing after IP injection of saline and morphine in the same animal controls for any within-animal specific breathing patterns. Third, we analyzed multiple parameters with and without averaging across breaths, in normoxia like Raehal *et al.*, and also in hypercapnia to more precisely quantify OIRD. This analysis and assays should reveal even a slight rescue of OIRD.

And finally, we validated our *in vivo* studies with *in vitro* studies measuring the impact of an
 130 opioid peptide directly on the *Arrb2* $-/-$ preBötC.

One difference between our study and the original *Arrb2* study³ was our method for
 morphine delivery. Raehal *et al.* reported that *Arrb2* knockouts lack any respiratory depression
 after 20 and 50mg/kg subcutaneous morphine. In contrast, controls showed a 20 and 35%
 depression, respectively. However even at the maximum morphine concentration (150mg/kg)
 135 controls only showed a 40% decrease in breathing frequency whereas in our study, although we
 deliver only 20mg/kg morphine by IP injection, we observe a profound 60% respiratory
 depression in normoxia and 30% in hypercapnia in *Arrb2* $+/+$, $+/-$, and $-/-$ mice. This respiratory
 depression exceeds what Raehal *et al.* reported and therefore should be sufficient to observe any
 OIRD rescue in *Arrb2* $-/-$ mice.

140 The core premise when developing biased agonists for MOR is that *Arrb2* provides a
 molecular mechanism to dissociate analgesia from respiratory depression. Our findings do not
 support this claim. How then do some biased agonists show analgesia while minimizing
 respiratory depression? Perhaps biased agonists are also partial agonists. In this case, if analgesia
 is more sensitive than respiratory depression to the concentration of opioids, then a partial
 145 agonist might enable these two effects to be separated. This would be akin to providing a lower
 dose of standard opioid drugs. Regardless, our results, along with similar data from another
 recent study¹⁸, call into question the foundational model that *Arrb2* selectively mediates OIRD
 and suggest that in the future, we must reconsider and reinvestigate the mechanism of biased
 agonism *in vivo*.

Materials and Methods

Key Resources Table				
Reagent type (species) or resource		Source or reference	Identifiers	Additional information
Genetic reagent (<i>Mus musculus</i>)	<i>Arrb2^{tm1Rj}/J</i>	The Jackson Laboratory	011130	RRID:IMSR_JAX:011130
Genetic reagent (<i>Mus musculus</i>)	C57BL/6J	The Jackson Laboratory	000664	RRID:IMSR_JAX:000664

Animals

*Arrb2*²⁰ has been described. *Arrb2* was bred to C57BL/6 and littermates (F1) were crossed to make *Arrb2*^{-/-}, *Arrb2*^{-/+}, and *Arrb2*^{+/+} (F2). Mice were housed in a 12-hour light/dark cycle with unrestricted food and water. Mice were given anonymized identities for experimentation and data collection. All animal experiments were performed in accordance with national and institutional guidelines with standard precautions to minimize animal stress and the number of animals used in each experiment.

Plethysmography and respiratory analysis

Plethysmography and respiratory analysis were performed as in⁷. Briefly, on the first recording day, adult (6-12 weeks) *Arrb2*^{-/-}, *Arrb2*^{-/+}, and *Arrb2*^{+/+} mice were administered IP 100μL of saline and placed in an isolated recovery cage for 15 minutes. After, individual mice were then

monitored in a 450 mL whole animal plethysmography chamber at room temperature (22°C) in
 165 21% O₂ balanced with N₂ (normoxia) or 21% O₂, 5% CO₂ balanced with N₂ (hypercapnia). After
 1 day, the same protocol was used to monitor breathing after IP injection of morphine (20mg/kg,
 Henry Schein 057202). Normoxia and hypercapnia morphine recordings were separated by at
 least 3 days. Each breath was automatically segmented based on airflow crossing zero as well as
 quality control metrics. Respiratory parameters (e.g. peak inspiratory flow, instantaneous
 170 frequency) for each breath, as well as averages, were then calculated. Reported airflow in
 mL/sec. is an approximate of true volumes. The analysis was performed with custom Matlab
 code available on Github with a sample dataset ([https://github.com/YackleLab/Opioids-depress-
 breathing-through-two-small-brainstem-sites](https://github.com/YackleLab/Opioids-depress-breathing-through-two-small-brainstem-sites)).

Statistics

175 A power analysis was performed using the reported effect size from Raehal *et al.*³. In this case,
 1-4 mice were necessary to observe a statistically significant result. Each cohort (*Arrb2*^{+/+}, *+/+*, -
-) exceeded 4. Statistical tests were performed on the ratio of IP morphine to IP saline for
 instantaneous respiratory frequency and peak inspiratory flow separately for normoxia and
 hypercapnia. A Shapiro Wilks test was first done to determine if the data was normally
 180 distributed. If normal, a single factor ANOVA was performed to determine any differences
 among the three genotypes (alpha <0.05). In the instance the P-value was <0.05, the Tukey HSD
 post-hoc test was done to determine which of the pairwise comparisons was statistically different
 (alpha<0.05). If the data failed to pass the Shapiro Wilks test, then the non-parametric Kruskal-
 Wallis test was used to determine if any differences (alpha<0.05). All the above statistics were

185 performed using the publicly available Excel package “Real Statistics Functions” SPSS and Matlab.

Slice electrophysiology

Rhythmic 550 to 650µm-thick transverse medullary slices which contain the preBötC and cranial nerve XII (XIIIn) from neonatal *Arrb2* ^{-/-} mice (P0-5) were prepared as described ⁷. Slices were
 190 cut in ACSF containing (in mM): 124 NaCl, 3 KCl, 1.5 CaCl₂, 1 MgSO₄, 25 NaHCO₃, 0.5 NaH₂PO₄, and 30 D-glucose, equilibrated with 95% O₂ and 5% CO₂ (4°C, pH=7.4). Recordings were performed in 9 mM at a temperature of 27°C. Slices equilibrated for 20 min before experiments were started. The preBötC neural activity was recorded from CNXII rootlet. Activity was recorded with a MultiClamp700A or B using pClamp9 at 10000 Hz and low/high
 195 pass filtered at 3/400Hz. After equilibration, baseline activity and then increasing concentrations of DAMGO (ab120674) were bath applied (20nM, 50nM, 100nM). After the rhythm was eliminated, 100nM Naloxone (Sigma Aldrich N7758) was bath applied to demonstrate slice viability. Rhythmic activity was normalized to the first control recording for dose response curves.

200

References

1. Scholl, L., Seth, P., Kariisa, M., Wilson, N. & Baldwin, G. Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. *MMWR. Morbidity and mortality weekly report* **67**, 1419–1427 (2018).
- 205 2. Pattinson, K. T. S. Opioids and the control of respiration. *British Journal of Anaesthesia* **100**, 747–758 (2008).
3. Raehal, K. M., Walker, J. K. L. & Bohn, L. M. Morphine Side Effects in β -Arrestin 2 Knockout Mice. *J Pharmacol Exp Ther* **314**, 1195–1201 (2005).
- 210 4. Turnaturi, R. *et al.* Progress in the development of more effective and safer analgesics for pain management. *Eur J Med Chem* **183**, 111701 (2019).
5. Dahan, A. *et al.* Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice. *Anesthesiology* **94**, 824–832 (2001).
- 215 6. Smith, J. C., Ellenberger, H. H., Ballanyi, K., Richter, D. W. & Feldman, J. L. Pre-Bötzinger complex: a brainstem region that may generate respiratory rhythm in mammals. **254**, 726–729 (1991).
7. Bachmutsky, I., Wei, X. P., Kish, E. & Yackle, K. Opioids depress breathing through two small brainstem sites. *eLife* **9**, (2020).
- 220 8. Varga, A. G., Reid, B. T., Kieffer, B. L. & Levitt, E. S. Differential impact of two critical respiratory centers in opioid-induced respiratory depression in awake mice. *The Journal of physiology* JP278612-37 (2019) doi:10.1113/jp278612.
9. Al-Hasani, R. & Bruchas, M. R. Molecular mechanisms of opioid receptor-dependent signaling and behavior. *Anesthesiology* **115**, 1363–1381 (2011).
- 225 10. Zurawski, Z., Yim, Y. Y., Alford, S. & Hamm, H. E. The expanding roles and mechanisms of G protein-mediated presynaptic inhibition. *Journal of Biological Chemistry* **294**, 1661–1670 (2019).
11. Luttrell, L. M. & Lefkowitz, R. J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. *Journal of cell science* **115**, 455–465 (2002).
12. Calebiro, D., Nikolaev, V. O., Persani, L. & Lohse, M. J. Signaling by internalized G-protein-coupled receptors. *Trends Pharmacol Sci* **31**, 221–228 (2010).
- 230 13. Montandon, G. *et al.* G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids. *Anesthesiology* **124**, 641–650 (2016).

14. Wei, A. D. & Ramirez, J.-M. Presynaptic Mechanisms and KCNQ Potassium Channels Modulate Opioid Depression of Respiratory Drive. *Frontiers in physiology* **10**, 1407 (2019).
15. Manglik, A. *et al.* Structure-based discovery of opioid analgesics with reduced side effects. *Nature* **537**, 185–190 (2016).
16. Schmid, C. L. *et al.* Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. *Cell* **171**, 1165–1175.e13 (2017).
17. Hill, R. *et al.* The novel μ -opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. *British journal of pharmacology* **175**, 2653–2661 (2018).
18. Kliewer, A. *et al.* Morphine-induced respiratory depression is independent of β -arrestin2 signalling. *Brit J Pharmacol* **177**, 2923–2931 (2020).
19. Bubier, J. A. *et al.* Genetic Variation Regulates Opioid-Induced Respiratory Depression in Mice. *Biorxiv* 2020.06.15.152249 (2020) doi:10.1101/2020.06.15.152249.
20. Bohn, L. M. *et al.* Enhanced Morphine Analgesia in Mice Lacking Beta-Arrestin 2. *Science* **286**, 2495–2498 (1999).

Funding: Yackle lab was supported by the University of California, San Francisco Program for Breakthrough in Biomedical Research and Sandler Foundation and a National Institutes of

250 Health Office of the Director Early Independence Award (DP5-OD023116). **Competing**

interests: None.

Figure 1. Basal respiration and OIRD in *Arrb2* littermates in normoxia. **a**, Breeding scheme to generate F2 littermates used in whole-body plethysmography breathing recordings after intraperitoneal (IP) saline injection to establish a baseline and after IP morphine (20mg/kg). **b**, Example breath after IP saline for *Arrb2* $+/+$ (wildtype, top) and *Arrb2* $-/-$ (homozygous knockout, bottom). Definition of peak inspiratory airflow (PIF, mL/sec.) and instantaneous frequency (Hz). Expir., Expiratory airflow. Insp., Inspiratory airflow. **c**, As in **b**, but example respiratory rhythm of many breaths. **d-e**, As in **b-c**, but example breaths are after IP morphine. **f**, Histogram of instantaneous respiratory frequency (Hz) for all breaths in *Arrb2* $-/-$ (red, combined from $n=7$ animals), *Arrb2* $+/-$ (green, $n=6$), and *Arrb2* $+/+$ (black, $n=5$) in morphine. PDF, probability density function. Top, mean (circle) $\pm$ standard deviation (bars). **g**, Ratio of average respiratory frequency in morphine to saline for *Arrb2* $-/-$ (0.380 ± 0.002), *Arrb2* $+/-$ (0.379 ± 0.002), and *Arrb2* $+/+$ (0.473 ± 0.001). Mean (circle) $\pm$ standard deviation (bars). Single Factor ANOVA,

$F(2,15) = 9.99$, P-value = 0.002. Tukey HSD post-hoc, *Arrb2*^{+/+} to +/- P-value = 0.004,

Arrb2^{+/+} to -/- P-value = 0.003, *Arrb2*^{+/-} to -/- P-value = 0.999. *, indicates the comparisons

with P-value <0.05. Note, *Arrb2* ^{+/+} mice have less respiratory depression, that is statistically

270 significant, when compared to *Arrb2* ^{+/-} and -/-. **h-i**, As in **f-g**, but for peak inspiratory airflow.

Arrb2^{-/-} (0.663±0.004), *Arrb2*^{+/-} (0.547±0.002), and *Arrb2*^{+/+} (0.676±0.014). Single Factor

ANOVA, $F(2,15) = 4.64$, P-value = 0.027. Tukey HSD post-hoc, *Arrb2*^{+/+} to +/- P-value = 0.04,

Arrb2^{+/+} to -/- P-value = 0.957, *Arrb2*^{+/-} to -/- P-value = 0.050. *, indicates the comparisons

with P-value <0.05. Note, *Arrb2* ^{+/-} mice have more depressed PIF, that is statistically

275 significant, when compared to *Arrb2* ^{+/+} and -/-. There is no statistically significant difference

between *Arrb2* ^{+/+} and -/-.

Figure 2. Breathing and OIRD in *Arrb2* littermates in hypercapnia. a-b, Example breaths

and breathing trace after IP saline for *Arrb2* +/+ (wildtype, top) and *Arrb2* -/- (homozygous knockout, bottom) in hypercapnia (5% CO₂, 21% O₂). **c-d**, As in **a-b**, but after IP morphine. **e**, Histogram of instantaneous respiratory frequency (Hz) for all breaths in *Arrb2* -/- (red, combined from n=7), *Arrb2* +/- (green, n=6), and *Arrb2* +/+ (black, n=5) after IP morphine. PDF, probability density function. Top, mean (circle) $\pm$ standard deviation (bars). **f**, Ratio of average respiratory frequency in morphine to saline for *Arrb2* -/- (0.679 $\pm$ 0.004), *Arrb2* +/- (0.627 $\pm$ 0.008), and *Arrb2* +/+ (0.654 $\pm$ 0.013). Mean (circle) $\pm$ standard deviation (bars). Kruskal-Wallis Test, P-value = 0.28. There is no statistically significant difference between the three genotypes. **g-h**, As in **g-h**, but for peak inspiratory airflow for *Arrb2* -/- (0.665 $\pm$ 0.001), *Arrb2* +/- (0.678 $\pm$ 0.010), and *Arrb2* +/+ (0.686 $\pm$ 0.003). Single Factor ANOVA, F(2,15) = 0.15, P-value = 0.86. There is no statistically significant difference between the three genotypes.

Figure 3. *Arrb2* ^{-/-} preBötC rhythmicity with the *Oprm1* agonist DAMGO. Left, Schematic

of the neonatal medullary slice preparation containing the preBötC and the hypoglossal motor

295 nucleus and nerve rootlet (CN12). Inspiratory bursts originating in the preBötC can be measured

by suction electrodes on the CN12 rootlet (jCN12). Right top, Bath application of 50nM

DAMGO. The rhythm disappears after DAMGO is fully washed on. Bottom, Bath application of

100nM Naloxone rescues the preBötC rhythm.